Literature DB >> 6745080

The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.

L B Sheiner.   

Abstract

Population pharmacokinetics describe the typical relationships between physiology (both normal and disease altered) and pharmacokinetics, the interindividual variability in these relationships, and their residual intraindividual variability. Knowledge of population kinetics can help one to choose initial drug dosage, to modify dosage appropriately in response to observed drug levels, to make rational decisions regarding certain aspects of drug regulation, and to investigate and elucidate certain research questions in pharmacokinetics. Experimental data from which population kinetics might be estimated often come from only those few individuals both willing and available to be studied. Clinical data from patients undergoing care might be more representative. These data, however, are marked by varying quality, accuracy, and precision, as well as there being few data per patient. Population pharmacokinetic parameters have traditionally been estimated either by fitting all individuals' data together as though there were no individual kinetic differences [the naive pooled data (NPD) approach], or by fitting each individual's data separately and then combining the individual parameter estimates [the two-stage (TS) approach]. These methods have certain theoretical problems which can only be aggravated when the deficiencies of data typical of clinical data are present. In this paper, the standard approaches are discussed and illustrated (using nondeficient data) in order to introduce subsequent papers in which alternative data analysis methods for population parameter estimation are defined, discussed, and compared.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6745080     DOI: 10.3109/03602538409015063

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  62 in total

1.  Information tools for exploratory data analysis in population pharmacokinetics.

Authors:  O Petricoul; L Claret; D Barbolosi; A Iliadis; C Puozzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

2.  The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat.

Authors:  Leon M Tai; Helmut Jacobsen; Laurence Ozmen; Alexander Flohr; Roland Jakob-Roetne; Antonello Caruso; Hans-Peter Grimm
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-04-06       Impact factor: 2.745

Review 3.  Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid.

Authors:  P Netter; B Bannwarth; M J Royer-Morrot
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

4.  Measuring the predictive performance of computer-controlled infusion pumps.

Authors:  J R Varvel; D L Donoho; S L Shafer
Journal:  J Pharmacokinet Biopharm       Date:  1992-02

5.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

6.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  Twitch potentiation influences the time course of twitch depression in muscle relaxant studies: a pharmacokinetic-pharmacodynamic explanation.

Authors:  Douglas J Eleveld; Johannes H Proost; J Mark K H Wierda
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-12       Impact factor: 2.745

8.  Population pharmacokinetic model for gatifloxacin in pediatric patients.

Authors:  Christopher M Rubino; Edmund V Capparelli; John S Bradley; Jeffrey L Blumer; Gregory L Kearns; Michael Reed; Richard F Jacobs; Brenda Cirincione; Dennis M Grasela
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

9.  Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.

Authors:  Sophie Callies; Valérie André; Bharvin Patel; David Waters; Paul Francis; Michael Burgess; Michael Lahn
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

10.  Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.

Authors:  Shinji Yamazaki
Journal:  AAPS J       Date:  2012-12-19       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.